Tags

Type your tag names separated by a space and hit enter

Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast.
Mod Pathol. 1990 Jul; 3(4):449-54.MP

Abstract

Cases of ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH) of the breast were examined for expression of the protein product of the c-erbB-2 (neu, HER-2) oncogene using two different polyclonal antibodies via an avidin-biotin immunoperoxidase method on formalin- or Bouin'-fixed, paraffin-embedded tissue. Fifty-five percent (18/33) of DCIS and 10% (2/21) of ADH were positive. Significant c-erbB-2 expression in DCIS was generally divided on histologic grounds: ten of ten comedocarcinomas showed strong membrane staining, while only one of 14 small cell DCIS cases (micropapillary or cribiform patterns) showed immunostaining (which was weak and basilar in this single case). DCIS cases of mixed histology were strongly positive in areas of comedocarcinoma. In two of three cases of associated Paget's disease strong membrane staining was seen. The two c-erbB-2-positive ADH cases showed weak basilar staining akin to the small cell DCIS cases. Five cases of lobular neoplasia (atypical lobular hyperplasia or lobular carcinoma in situ) associated with DCIS or ADH were negative for c-erbB-2 expression. We conclude that comedocarcinoma in situ and Paget's disease frequently express the c-erbB-2 protein and are both histologically and biochemically distinct from ADH and small cell patterns of DCIS. We advocate precise subclassification of DCIS on histopathologic reports, particularly in view of reports that overexpression of the c-erbB-2 oncogene in infiltrating breast carcinomas may be associated with a poor prognosis.

Authors+Show Affiliations

Department of Pathology, University of Pennsylvania School of Medicine, Philadelphia.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

2170971

Citation

Lodato, R F., et al. "Immunohistochemical Evaluation of c-erbB-2 Oncogene Expression in Ductal Carcinoma in Situ and Atypical Ductal Hyperplasia of the Breast." Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, vol. 3, no. 4, 1990, pp. 449-54.
Lodato RF, Maguire HC, Greene MI, et al. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol. 1990;3(4):449-54.
Lodato, R. F., Maguire, H. C., Greene, M. I., Weiner, D. B., & LiVolsi, V. A. (1990). Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc, 3(4), 449-54.
Lodato RF, et al. Immunohistochemical Evaluation of c-erbB-2 Oncogene Expression in Ductal Carcinoma in Situ and Atypical Ductal Hyperplasia of the Breast. Mod Pathol. 1990;3(4):449-54. PubMed PMID: 2170971.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. AU - Lodato,R F, AU - Maguire,H C,Jr AU - Greene,M I, AU - Weiner,D B, AU - LiVolsi,V A, PY - 1990/7/1/pubmed PY - 2001/3/28/medline PY - 1990/7/1/entrez SP - 449 EP - 54 JF - Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc JO - Mod Pathol VL - 3 IS - 4 N2 - Cases of ductal carcinoma in situ (DCIS) and atypical ductal hyperplasia (ADH) of the breast were examined for expression of the protein product of the c-erbB-2 (neu, HER-2) oncogene using two different polyclonal antibodies via an avidin-biotin immunoperoxidase method on formalin- or Bouin'-fixed, paraffin-embedded tissue. Fifty-five percent (18/33) of DCIS and 10% (2/21) of ADH were positive. Significant c-erbB-2 expression in DCIS was generally divided on histologic grounds: ten of ten comedocarcinomas showed strong membrane staining, while only one of 14 small cell DCIS cases (micropapillary or cribiform patterns) showed immunostaining (which was weak and basilar in this single case). DCIS cases of mixed histology were strongly positive in areas of comedocarcinoma. In two of three cases of associated Paget's disease strong membrane staining was seen. The two c-erbB-2-positive ADH cases showed weak basilar staining akin to the small cell DCIS cases. Five cases of lobular neoplasia (atypical lobular hyperplasia or lobular carcinoma in situ) associated with DCIS or ADH were negative for c-erbB-2 expression. We conclude that comedocarcinoma in situ and Paget's disease frequently express the c-erbB-2 protein and are both histologically and biochemically distinct from ADH and small cell patterns of DCIS. We advocate precise subclassification of DCIS on histopathologic reports, particularly in view of reports that overexpression of the c-erbB-2 oncogene in infiltrating breast carcinomas may be associated with a poor prognosis. SN - 0893-3952 UR - https://www.unboundmedicine.com/medline/citation/2170971/Immunohistochemical_evaluation_of_c_erbB_2_oncogene_expression_in_ductal_carcinoma_in_situ_and_atypical_ductal_hyperplasia_of_the_breast_ L2 - https://medlineplus.gov/breastcancer.html DB - PRIME DP - Unbound Medicine ER -